Nebivolol Clinical Trials

Size	Price	Qty
5mg	USD 147

Clinical Trials

Numerous clinical trials spanning Early Phase 1 through Phase 4 evaluate nebivolol across diverse cardiovascular and metabolic conditions, including essential hypertension, heart failure, pre-hypertension, type 2 diabetes mellitus, and erectile dysfunction, alongside drug-drug interaction studies in idiopathic pulmonary fibrosis. Sponsored by pharmaceutical companies and academic research institutions, these studies range from early pharmacokinetic assessments to extensive post-marketing safety and efficacy investigations. Although many trials are completed, others remain actively recruiting, terminated, withdrawn, or of unknown status.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04432610	WITHDRAWN	Bisoprolol Adverse Reaction; Nebivolol Adverse Reaction	Clinical Hospital Center Zemun	2030-01	PHASE4
NCT06249802	NOT_YET_RECRUITING	Intracranial Aneurysm	Jagiellonian University	2025-01-01	PHASE4
NCT07568574	ENROLLING_BY_INVITATION	Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes	Enhanced Emirates Limited	2026-03-12
NCT07233499	RECRUITING	HER2-positive Breast Cancer	Ain Shams University	2025-01-01	PHASE2
NCT06424834	RECRUITING	Angina Pectoris; Microvascular Angina; Vasospastic Angina; Myocardial Bridge of Coronary Artery	Stanford University	2024-10-10	PHASE2; PHASE3
NCT06035978	UNKNOWN	Cardiovascular Diseases; Heart Failure With Reduced Ejection Fraction	University Hospital Ostrava	2024-03	PHASE4
NCT06201611	RECRUITING	Diabetic Neuropathy Peripheral	St. John's Research Institute	2024-11-15	PHASE2; PHASE3
NCT03778554	ACTIVE_NOT_RECRUITING	Acute Myocardial Infarction; Non-ST Elevation Myocardial Infarction (nSTEMI); ST Elevation Myocardial Infarction	Bispebjerg Hospital	2018-12-17	PHASE4
NCT07397481	COMPLETED	Liver Cirrhosis; Arterial Hypertension	Kafrelsheikh University	2024-03-01	PHASE4
NCT06248099	UNKNOWN	Healthy Subjects	Bio-innova Co., Ltd	2024-07-09	PHASE1
NCT06104423	COMPLETED	Hypertension	Menarini International Operations Luxembourg SA	2023-10-02	PHASE4
NCT06004453	Recruiting	Heart Failure	Novartis Pharmaceuticals\|Novartis	2023-04-04	--
NCT05728632	UNKNOWN	Breast Cancer; Lymphoma, Large B-Cell, Diffuse; Cardiotoxicity; Left Ventricular Dysfunction; Chemotherapy Effect	Giulio Stefanini	2019-01-01	PHASE3
NCT05328310	UNKNOWN	Hypertension	Korea University Anam Hospital	2019-01-06
NCT05513937	COMPLETED	Hypertension	Menarini International Operations Luxembourg SA	2022-05-12	PHASE4
NCT04513509	COMPLETED	Atrial Fibrillation; Rate Control; Cardiopulmonary Exercise Test	National Taiwan University Hospital	2020-10-21
NCT04910100	COMPLETED	Open-Angle Glaucoma; Ocular Hypertension	Betaliq, Inc.	2021-04-15	PHASE2
NCT04631536	UNKNOWN	Covid19	Lebanese American University Medical Center	2021-01-10	PHASE3
NCT04130438	TERMINATED	Myocardial Bridging	Stanford University	2020-10-15	PHASE2
NCT05257148	COMPLETED	Hypertension	Menarini International Operations Luxembourg SA	2021-05-26	PHASE4
NCT04845061	UNKNOWN	Copd	Ain Shams University	2021-10-01	PHASE4
NCT01648634	COMPLETED	Duchenne Muscular Dystrophy; Cardiomyopathy; Heart Failure	Assistance Publique - Hôpitaux de Paris	2012-02-13	PHASE3
NCT04888728	COMPLETED	Idiopathic Pulmonary Fibrosis	Daewoong Pharmaceutical Co. LTD.	2021-06-30	PHASE1
NCT04888728	Completed	Idiopathic Pulmonary Fibrosis	Daewoong Pharmaceutical Co. LTD.	2021-06-30	Phase 1
NCT02053246	TERMINATED	Pulmonary Hypertension; Diastolic Heart Failure; Heart Failure With Preserved Ejection Fraction	University of Florida	2014-01	PHASE4
NCT03655964	COMPLETED	Stroke, Ischemic	Aristotle University Of Thessaloniki	2018-08-20	PHASE2
NCT03930433	COMPLETED	Coronary Vasospasm	Korea University Anam Hospital	2018-01-01	PHASE4
NCT02619526	UNKNOWN	Heart Failure	Dong-A University	2016-12
NCT03180593	COMPLETED	Hypertension Complicated; Hypertrophy, Left Ventricular; Blood Pressure	Trinity Hypertension & Metabolic Research Institute	2017-02-07	PHASE4
NCT02467400	COMPLETED	Osteoporosis, Age-Related	Mayo Clinic	2015-07-01	EARLY_PHASE1
NCT01595516	COMPLETED	Prehypertension; Hypertension	University of Colorado, Boulder	2012-02	PHASE4
NCT00223717	COMPLETED	Hypertension	Vanderbilt University	2001-01	PHASE1
NCT01395329	COMPLETED	Prehypertension; Hypertension	University of Colorado, Boulder	2011-05	PHASE4
NCT01522950	COMPLETED	Hypertension	University of Minnesota	2010-05	PHASE2
NCT03245996	COMPLETED	Aortic Blood Pressure	Tartu University Hospital	2015-06	PHASE4
NCT01996085	COMPLETED	Arterial Hypertension	Military Institute od Medicine National Research Institute	2013-01
NCT02710071	COMPLETED	Hypertension	University of California, San Diego	2015-01	PHASE4
NCT01961323	COMPLETED	Hypertension; Left Ventricular Diastolic Dysfunction	Icahn School of Medicine at Mount Sinai	2012-03	PHASE4
NCT01771406	UNKNOWN	Hypertension; Endothelial Dysfunction; Obstructive Sleep Apnea	Universitaire Ziekenhuizen KU Leuven	2013-02	PHASE4
NCT01501929	COMPLETED	Hypertension	University of Texas Southwestern Medical Center	2010-08	PHASE4
NCT03847350	Completed	Essential Hypertension	A.Menarini Asia-Pacific Holdings Pte Ltd	2015-07-01	--
NCT01665508	COMPLETED	Microvascular Angina	Massachusetts General Hospital	2013-04	PHASE4
NCT02057328	UNKNOWN	Hypertension	Aristotle University Of Thessaloniki	2010-12	PHASE4
NCT05170061	COMPLETED	Hypertension	State University of New York at Buffalo	2013-02	PHASE3
NCT01157234	COMPLETED	Hypertension	University of Florida	2010-07	PHASE4
NCT01044693	COMPLETED	Hypertension; Pure Autonomic Failure; Multiple System Atrophy	Vanderbilt University	2010-01
NCT01499134	COMPLETED	Peripheral Artery Disease; Hypertension	Thomas Jefferson University	2011-08	PHASE3
NCT01885988	UNKNOWN	Erectile Dysfunction	Martin M. Miner, MD	2013-03	PHASE4
NCT01041287	COMPLETED	Hypertension	Emory University	2009-12	PHASE4
NCT01056718	COMPLETED	Hypertension	Mercy Research	2009-11
NCT01230892	COMPLETED	Atherosclerosis; Endothelial Function	Emory University	2010-02	PHASE4
NCT01679652	COMPLETED	Essential Hypertension	Erling Bjerregaard Pedersen	2012-08	PHASE2
NCT01441570	TERMINATED	Transplant; Failure, Kidney; Hypertension	Brigham and Women's Hospital	2012-02
NCT00683124	UNKNOWN	Marfan Syndrome	Fondazione IRCCS Policlinico San Matteo di Pavia	2008-07	PHASE3
NCT01502787	COMPLETED	Hypertension	University of Texas Southwestern Medical Center	2009-04	PHASE4
NCT00995072	COMPLETED	Hypertension; Female Sexual Dysfunction	East Coast Institute for Research	2009-10
NCT01508026	COMPLETED	Stage 1 Hypertension; Stage 2 Hypertension	Forest Laboratories	2012-01	PHASE3
NCT01939990	WITHDRAWN	High Blood Pressure	University of Chicago	2012-01	PHASE2; PHASE3
NCT01605370	TERMINATED	Hypertension	Mayo Clinic	2012-06	PHASE4
NCT01885988	Unknown status	Erectile Dysfunction	Martin M. Miner MD\|Forest Laboratories\|The Miriam Hospital	2013-03	Phase 4
NCT01358409	COMPLETED	Cardiac Steatosis and Lipotoxicity	Lidia Szczepaniak	2011-04-01	EARLY_PHASE1
NCT01415505	COMPLETED	Hypertension	Forest Laboratories	2011-08	PHASE3
NCT01206439	TERMINATED	Hypertension	Jack Rubinstein	2010-09	PHASE4
NCT01920282	COMPLETED	Hypertension	Virginia Polytechnic Institute and State University	2010-01	PHASE4
NCT01049009	COMPLETED	High Blood Pressure	Emory University	2009-12	PHASE4
NCT00893984	TERMINATED	Coronary Artery Disease	Minneapolis Heart Institute Foundation	2009-05	PHASE4
NCT01202175	COMPLETED	Pre-hypertension; Hypertension	University of California, San Diego	2010-07	PHASE4
NCT00829296	COMPLETED	Hypertension; Diabetes	University of Chicago	2009-01	PHASE2; PHASE3
NCT01415531	COMPLETED	Hypertension	Forest Laboratories	2011-08	PHASE4
NCT00992056	COMPLETED	Hypertension	University of Miami	2010-12	PHASE4
NCT03517020	COMPLETED	Healthy Subjects	Torrent Pharmaceuticals Limited	2011-04	PHASE1
NCT03517033	COMPLETED	Healthy Subjects	Torrent Pharmaceuticals Limited	2011-05	PHASE1
NCT00775671	COMPLETED	Metabolic Syndrome	Vanderbilt University	2008-10	PHASE4
NCT03635125	COMPLETED	JNC 7 Stage 1 or 2 Hypertension	Trinity Hypertension & Metabolic Research Institute	2010-08-30	PHASE4
NCT01218100	COMPLETED	Stage 2 Diastolic Hypertension	Forest Laboratories	2010-10	PHASE4
NCT01076140	WITHDRAWN	Hypertension	University of Mississippi Medical Center	2010-02
NCT00999102	COMPLETED	Hypertension	Weill Medical College of Cornell University	2009-10	PHASE4
NCT01057251	COMPLETED	Hypertension	Forest Laboratories	2010-03	PHASE4
NCT00849810	TERMINATED	Hypertension	University of Mississippi Medical Center	2009-01
NCT00673790	COMPLETED	Hypertension	Forest Laboratories	2008-05-15	PHASE4
NCT00744237	COMPLETED	Hypertension; Type 2 Diabetes Mellitus	Forest Laboratories	2008-08	PHASE4
NCT01051947	WITHDRAWN	Central Aortic Pressure	Creighton University	2009-12
NCT00734630	COMPLETED	Hypertension	Forest Laboratories	2008-08	PHASE4
NCT01057251	Completed	Hypertension	Forest Laboratories	2010-03	Phase 4
NCT00999752	COMPLETED	Hypertension	InVasc Therapeutics, Inc.	2009-10
NCT00770861	COMPLETED	Hypertension	Forest Laboratories	2008-09	PHASE4
NCT00673075	COMPLETED	Hypertension; Coronary Artery Disease	Forest Laboratories	2008-05	PHASE4
NCT00785512	COMPLETED	Hypertension	Forest Laboratories	2008-11	PHASE4
NCT00648895	COMPLETED	Hypertension	Forest Laboratories	2007-11	PHASE3
NCT00295542	COMPLETED	Hypertension	University of Vigo	2000-03	PHASE4
NCT00125853	COMPLETED	Hypertension	Imperial College London	2006-07
NCT01248338	COMPLETED	Hypertension	Berlin-Chemie AG Menarini Group	2006-03	PHASE4
NCT00942487	COMPLETED	Primary Arterial Hypertension	Berlin-Chemie Menarini	2005-04	PHASE3
NCT00142584	COMPLETED	Hypertension	Mylan Bertek Pharmaceuticals	2005-08	PHASE3
NCT00547300	TERMINATED	Hypertension	Forest Laboratories	2007-10-31	PHASE3
NCT00145210	COMPLETED	Hypertension	Mylan Bertek Pharmaceuticals	2005-04	PHASE3
NCT00924833	COMPLETED	Hypoxia; Altitude; Heart Failure	Istituto Auxologico Italiano	2006-05	PHASE4
NCT00145236	COMPLETED	Hypertension	Mylan Bertek Pharmaceuticals	2001-11	PHASE3
NCT00517725	COMPLETED	Chronic Heart Failure	Centro Cardiologico Monzino	2007-07	PHASE4
NCT00200434	COMPLETED	Hypertension	Mylan Bertek Pharmaceuticals	2002-10	PHASE3
NCT00200499	COMPLETED	Hypertension	Mylan Bertek Pharmaceuticals	2002-03	PHASE3
NCT00200473	COMPLETED	Hypertension	Mylan Bertek Pharmaceuticals	2001-09	PHASE3
NCT00200421	COMPLETED	Hypertension	Mylan Bertek Pharmaceuticals	2002-05	PHASE2
NCT00200460	COMPLETED	Hypertension	Mylan Bertek Pharmaceuticals	2001-09	PHASE3
NCT00158093	COMPLETED	Hypertension	Mylan Bertek Pharmaceuticals	2003-06	PHASE1

(data from https://clinicaltrials.gov, updated on 2022-12-20)

Check the Nebivolol product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Nebivolol selectively binds to and antagonizes beta-1 adrenergic receptors while stimulating endothelial nitric oxide synthase activity, thereby inhibiting catecholamine-mediated cyclic adenosine monophosphate production and enhancing vascular nitric oxide synthesis. This dual mechanism induces peripheral vasodilation and reduces cardiac workload and systemic vascular resistance, providing therapeutic benefit in clinical conditions such as essential hypertension and heart failure.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).